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Abstract
Objectives—Many prescription medications have limited information regarding safety for use 
during pregnancy. In order to inform research on safer medication use during pregnancy, we 
examined prescription medication use among women in the United States.
Methods—We analyzed data from the 1999–2006 National Health and Nutrition Examination 
Survey (NHANES) to estimate the prevalence of prescription medication use in the past 30 days 
among pregnant women and non-pregnant women of childbearing age (15–44 years) and to 
ascertain the most commonly reported prescription medications by women in these groups. We 
assessed how the most commonly reported medications differed among groups defined by selected 
demographic characteristics, including age, race/ethnicity, and markers of socioeconomic status.
Results—Prescription medication use in the past 30 days was reported by 22% of pregnant 
women and 47% of non-pregnant women of childbearing age. The most commonly reported 
prescription medications by NHANES participants differed somewhat by pregnancy status; allergy 
and anti-infective medications were more common among pregnant women, while oral 
contraceptives were more common among non-pregnant women. Use of prescription medication 
for asthma and thyroid disorders was reported by both groups.
Conclusions—Although prescription medication use in the previous 30 days was less common 
among pregnant women than non-pregnant women, its use was reported among almost 1 in 4 
pregnant women. Many of the most common medications reported were for the treatment of 
chronic medical conditions. Given the potential impact of medications on the developing fetus, our 
data underscore the importance of understanding the safety of these medications during 
pregnancy.
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Treating medical conditions in pregnant women is complicated by the need to balance the 
potential risk of medication exposures to the developing fetus with the potential risks to the 
health of the mother and the fetus if a condition is not treated. In order to weigh these risks, 
women and health care providers need to have reliable information on the safety of 
medication use during pregnancy. Substantial research gaps regarding medication safety 
during pregnancy have been well documented (1–5). A key step to guide this research is to 
characterize medication use among pregnant women and women capable of becoming 
pregnant (often operationalized as non-pregnant women of childbearing age). Many 
European countries have documented the prevalence of medication dispensing in their 
populations using robust population-wide registry data sources (6–11). Capturing 
medication exposure information for the U.S. population must rely on data from multiple 
data sources, each with unique strengths and limitations.
Some North American-based data sources, primarily population-based case-control studies 
and health plan database studies, have documented the prevalence of medication use during 
pregnancy, from 60% up to nearly 90%, and an increase in medication use over time (12–
14). The prevalence of medication use among non-pregnant women of childbearing age is 
not well-understood. Understanding medication use among this population is important 
because 51 percent of pregnancies in the U.S. are unintended (15) and many pregnancies are 
not recognized early in the first trimester (16) when organogenesis occurs (17). A survey of 
an adult population in the U.S. conducted in 1998–1999 found that 82% of women age 18–
44 years reported any use of a prescription or over-the-counter medication or a vitamin, 
mineral, or herbal supplement; results were not stratified by pregnancy status, however (18).
Our objective for the current investigation was to examine the prevalence of prescription 
medication use among women in the National Health and Nutrition Examination Survey 
(NHANES), a nationally representative cross-sectional survey (19–22). Because NHANES 
oversampled pregnant women in 1999–2006 (23), we were able to estimate prevalence of 
prescription medication use among both pregnant women and non-pregnant women of 
childbearing age and to identify the most commonly reported prescription medications used 
in the past 30 days by each group.
METHODS
Data Source
We analyzed data from NHANES, an ongoing, multistage sample survey used to monitor 
the health and nutritional status of the U.S. civilian, non-institutionalized population. 
Detailed methods for NHANES are provided elsewhere (19–22). Briefly, NHANES consists 
of an in-person interview and a physical examination. NHANES is currently conducted 
annually, and data are publicly released in two-year cycles. Data for this analysis came from 
the 1999 – 2006 cycles. All study participants provided informed consent, and the study 
protocol received approval from the National Center for Health Statistics Ethical Review 
Board.
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During the interview participants were asked, “In the past month, have you used or taken 
medication for which a prescription is needed?” Participants reporting prescription 
medication use were then asked to show the prescription medication container, if available, 
so that the interviewer could record relevant information; no exclusions were made based on 
availability of the prescription container. Reported medications were classified using Cerner 
Multum’s Lexicon Plus® drug database. Dietary supplements reported in response to this 
question were not included in the analysis.
We used the NHANES variable “RIDEXPRG” to ascertain pregnancy status. A woman was 
coded as pregnant if she reported being pregnant in the questionnaire or if she tested positive 
during a urine pregnancy test. We included data from the 1999 – 2006 cycles because during 
this time period pregnant women were oversampled in NHANES, providing sufficient 
statistical stability to make nationally representative estimates. All pregnant women 
screened during these years were included in the survey. Beginning in the 2007 – 2008 
survey cycle, pregnant women were no longer oversampled, and the number of pregnant 
women included in the survey population dropped dramatically. We defined non-pregnant 
women of childbearing age as those women who did not report being pregnant or test 
positive on the pregnancy test and who were age 15 to 44 years (only 6 pregnant women 
were outside of this age range); the term “non-pregnant women” will be used to refer to this 
group. Women for whom pregnancy status could not be determined were excluded (N=743).
Analysis
Analyses were stratified by pregnancy status. Because research has shown that fetal effects 
of medication use during pregnancy may differ among various medications within a 
particular class (24), our study focused on specific medications rather than on broader 
medication classes or anatomical classification codes. We identified the reported 
prescription medication products by their generic drug names. We did not distinguish 
between different salts of the same active ingredient and combined all insulin-containing 
medications. We calculated the appropriate 8-year sampling weights (25). We estimated the 
distribution of the total number of prescription medications reported and determined which 
prescription medications were most commonly reported. We estimated the percentage of 
non-pregnant women that used each of these medications. Sample size was not sufficient to 
allow us to report these percentages for pregnant women, or to compare the percentages of 
pregnant and non-pregnant women that reported using specific medications. We identified 
the five most common medications reported among non-pregnant women stratified by 
categories defined by age, race/ethnicity, education level, poverty income ratio (PIR, defined 
as the ratio of self-reported family income to federal poverty threshold, accounting for 
family size, year, and state; higher values indicate higher socioeconomic status (26)), parity, 
and breastfeeding status; we were not able to consider these categories for pregnant women 
due to limited sample size. Analyses were conducted in SAS-callable SUDAAN version 11 
(Research Triangle Institute, Research Triangle Park, NC, USA) using the “SDMVPSU” 
and “SDMVSTRA” variables for the masked variance pseudo-primary sampling unit and 
masked variance pseudo-stratum, respectively, to account for the complex survey design in 
our estimation of variance.
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The 1999 – 2006 NHANES included data on 1,350 pregnant women and 5,484 non-pregnant 
women. Based on weighted percentages, over half of the pregnant women were between the 
ages of 25 and 34, with fewer than 15% of women in this group age 35 years or older. In 
contrast, almost 40% of non-pregnant women were age 35 years or older. A higher 
percentage of non-pregnant women were non-Hispanic white, and a higher percentage of 
pregnant women were Mexican American. We observed little difference in the highest level 
of education attained or PIR category among pregnant and non-pregnant women. Not 
including their current pregnancy, pregnant women were more likely to have had a previous 
pregnancy than non-pregnant women. Among non-pregnant women, 2.5% reported that they 
were currently breastfeeding. Among pregnant women who self-reported that they were 
pregnant, approximately 24% reported being in their first trimester, 40% in their second 
trimester, and 36% in their third trimester (Table 1).
Prescription medication use in the past 30 days was reported among 22.2% of pregnant 
women (95% CI: 19.0%, 25.8%); non-pregnant women reported prescription medication use 
approximately twice as frequently (47.0%, 95% CI: 45.0%, 49.0%) (Figure 1). Among 
pregnant women who reported prescription medication use in the past 30 days, 72.8% (95% 
CI: 61.7%, 81.6%) reported use of only one medication. Among non-pregnant women who 
reported prescription medication use in the previous 30 days, about half reported use of one 
medication (47.7%, 95% CI: 45.7%, 49.8%) and half reported the use of two or more 
(52.3%, 95% CI: 50.2%, 54.4%). We were not able to further categorize the non-pregnant 
women reporting 2 or more medications (e.g. 2 vs. 3 or more) because of small numbers.
Among pregnant women the most commonly reported medication was levothyroxine, which 
is used to treat thyroid disorders. Three antibiotics – amoxicillin, nitrofurantoin, and the 
combination of sulfamethoxazole and trimethoprim – were among the most common 
prescription medications used by pregnant women. Certain asthma and allergy medications 
were also among the most commonly reported prescription medications; specifically 
albuterol, montelukast, cetirizine, budenoside, and promethazine, the last of which is more 
commonly prescribed for nausea and vomiting. Insulin was also among the 10 most 
frequently reported medications taken in the previous 30 days among pregnant women 
(Table 2). We were not able to estimate the percentage of pregnant women taking these 
medications, or compare these percentages to the percentages for non-pregnant women, due 
to small sample size.
Among non-pregnant women the most commonly reported prescription medication used in 
the previous 30 days was the combination of ethinyl estradiol and norgestimate, an oral 
contraceptive, use of which was reported by 3.7% of women in this group (95% CI: 2.9%, 
4.7%). Two other oral contraceptives – the combination of ethinyl estradiol and 
norethindrone and the combination of ethinyl estradiol and levonorgestrel – were also 
among the 10 most commonly reported prescription medications used in the previous 30 
days by non-pregnant women, used by 2.7% and 2.2%, respectively. Three selective 
serotonin reuptake inhibitors (SSRIs), used to treat conditions including depression and 
anxiety, were among the most commonly reported medications for non-pregnant women, 
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each reported by approximately 2% of women in this group. Pain relievers, specifically 
prescription-strength ibuprofen, used by 2.7% (95% CI: 2.2%, 3.4%), and the combination 
of acetaminophen and hydrocodone, used by 2.2% (95% CI: 1.7%, 2.8%), were also among 
the 10 prescription medications most commonly reported by non-pregnant women (Table 2).
Only levothyroxine and albuterol were included in the list of the 10 most commonly 
reported prescription medications used in the past 30 days among both pregnant women and 
non-pregnant women. Levothyroxine was reported by 3.4% (95% CI: 2.7%, 4.3%), and 
albuterol was reported by 2.9% (95% CI: 2.3%, 3.6%) of non-pregnant women.
For non-pregnant women, oral contraceptives were more often in the top five reported 
prescription medications among younger women, women with higher education, women in a 
higher PIR category, non-Hispanic white women, and nulliparous women. Norethindrone, a 
progestin-only oral contraceptive, was in the list of the five most common medications for 
breastfeeding women. Prescription pain medications and albuterol were present among the 
five most common medications for the majority of sociodemographic categories considered. 
For non-pregnant women age 35 to 44 years levothyroxine and fluoxetine were among the 
five most commonly reported prescription medications. Non-Hispanic white women were 
the only racial/ethnic group with SSRIs among the five most commonly reported 
medications. Hydrochlorothiazide, an antihypertensive, was reported only in the list of the 
five most common medications for non-Hispanic blacks; amoxicillin was reported only 
among the top five most common medications for Mexican Americans, and cetirizine, an 
antihistamine, was reported only in the list of the most common medications for the “other” 
racial/ethnic category (Table 3).
DISCUSSION
We observed that reported prescription medication use in the past 30 days was half as 
common among pregnant women compared to non-pregnant women, and pregnant women 
who reported prescription medication use were more likely to report use of only one 
prescription medication. These differences have several possible explanations. 
Approximately 17% of U.S. women age 15–44 years used oral contraceptives in 2006–2008 
(27), but given that these medications are designed to prevent pregnancy they are 
contraindicated and rarely used during pregnancy. Women may discontinue medication use 
upon pregnancy recognition, healthcare providers may be less likely to prescribe 
medications to pregnant women, or pregnant women may be less likely to take prescribed 
medications (28–30). In a survey of obstetrician gynecologists, Morgan and colleagues 
found that almost 50% of survey respondents reported that they did not prescribe 
medications to treat certain maternal conditions because of lack of data on medication safety 
(31). Pregnant women may assume that over-the-counter (OTC) medications are safer than 
prescription medications and may manage symptoms with OTC medications not captured in 
this analysis. Werler and colleagues reported increased prevalence of use for specific OTC 
medications during pregnancy when compared to the three months before pregnancy (14). 
Lastly, the fact that in our sample non-pregnant women were generally older than pregnant 
women could help to explain their higher medication use; older age is associated with 
increased prescription medication utilization (32, 33).
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Differences in the types of medications most frequently reported by pregnant and non-
pregnant women were also observed. Oral contraceptives were the most frequently reported 
prescription medications among non-pregnant women, comprising three of the 10 most 
common medications reported by this group. This observation is consistent with previously 
published reports that oral contraceptives are the most frequently used prescription 
medications among U.S. women age 18–44 years (18, 27). As expected, oral contraceptives 
were not among the most commonly used medications among pregnant women during the 
past 30 days. We conducted a sensitivity analysis in which oral contraceptives were 
excluded. Fexofenadine, an allergy medication, amoxicillin, an antibiotic, and bupropion, a 
medication used to treat depression or for smoking cessation, were then included in the list 
of 10 most common medications taken by this group.
We observed other noteworthy differences in medications used between pregnant and non-
pregnant women. Pain medications and SSRIs were among the most commonly reported 
medications by non-pregnant woman, but not by pregnant women. This difference may 
indicate reluctance on the part of healthcare providers to prescribe medications for certain 
clinical indications during pregnancy (31). The use of opioid pain medications among 
women in the U.S. is a growing concern, with a 415% increase in overdose deaths between 
1999 and 2010 (34). A recent analysis showed that the proportion of pregnant women 
covered by Medicaid who filled prescriptions for an opioid during pregnancy increased from 
18.5% in 2000 to 22.8% in 2007 (35). Though not among the most commonly used 
medications during pregnancy, the use of opioid pain medications during pregnancy is also 
of concern due to the challenges of treating neonatal abstinence syndrome (36, 37) and the 
potential for increased risk of certain birth defects (selected heart defects, spina bifida, and 
gastroschisis) (38). Insulin was one of the most common medications reported by pregnant 
women, which is likely related to its use in managing gestational diabetes, which is 
estimated to occur in 2 – 10% of pregnancies (39). Some of the differences we observed 
may reflect uncertainty on the part of healthcare providers on how best to weigh the risks 
and benefits of medication use during pregnancy. Differences in sociodemographic 
characteristics, particularly age, may also contribute to differences in patterns of prescription 
medication use.
The frequently reported use of albuterol and levothyroxine in both groups of women 
suggests that asthma and certain thyroid conditions are among the more prevalent chronic 
conditions requiring prescription medication for woman of childbearing age. In an analysis 
of multiple national health surveys using data from 1997–2001, the prevalence of current 
asthma was estimated to be between 3.7%–8.3% and 5.0%–9.4%, among pregnant women 
and non-pregnant women of childbearing age, respectively(40). Previously published studies 
report the prevalence of overt hypothyroidism in pregnancy to be 1.4%–2.2% (41–44). Both 
untreated asthma and hypothyroidism have been associated with maternal and fetal 
complications (45–48). In addition, physiological and endocrine changes throughout 
pregnancy may increase symptom frequency or severity necessitating close clinical 
monitoring to maintain the efficacy of a given treatment throughout gestation (49–51). The 
prevalence of medication use to treat these conditions highlights the importance of 
understanding the safety profile of these medications during pregnancy and how best to 
manage these conditions in pregnant women.
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Previously published studies report a higher prevalence of prescription medication use 
during pregnancy than was observed in our analysis, 64%–70% (12, 13). Several factors 
likely contributed to the lower prevalence of use that we observed (22%), with the greatest 
being that the time period of use queried in NHANES was only the previous 30 days, rather 
than the entire pregnancy. In addition, in the current analysis medication use was recorded 
based on women’s self-report in response to a single question within a structured interview. 
Previous studies have utilized data from multiple medication-specific questions or large 
health maintenance organization prescription databases. However, our results regarding the 
most commonly reported prescription medications used during pregnancy are similar to 
results in previously published reports (5, 12, 13).
This analysis contributes to the literature by providing updated prevalence estimates for 
recent prescription medication use among a nationally representative sample of non-
pregnant women of childbearing age. A 1998–1999 U.S. survey found that 46% of women 
18–44 years of age reported using at least one prescription medication within the past week 
(18). Similar to our findings, oral contraceptives, levothyroxine, albuterol, and SSRIs were 
among the most frequently reported prescription medications in that study. Medication use 
among non-pregnant women of childbearing age is important to understand because over 
half of pregnancies are unintended according to 2008 U.S. data (15). Pregnancy recognition 
can take several weeks(16) and therefore understanding prescription utilization patterns 
among non-pregnant women of childbearing age is important to anticipating unintentional 
medication exposures during the first trimester, a critical time of organogenesis (17).
We observed notable differences in patterns of contraceptive use among non-pregnant 
women (Table 3). When stratified by race/ethnicity, oral contraceptives were reported 
among the five most commonly reported prescription medications only for non-Hispanic 
white women. Previous studies have reported that reproductive health service utilization 
varies by sociodemographic characteristics; in particular, non-white women are less likely to 
use contraceptives overall and use different contraceptive methods than non-Hispanic white 
women (27, 52). Contraceptive methods that do not require a prescription (e.g. condoms) or 
long-acting reversible contraceptive methods (e.g., subdermal contraceptive implant) would 
not be captured in our results. In addition, previous studies have reported that non-white 
women have higher rates of chronic disease, including asthma, diabetes, and hypertension 
(46, 53, 54). Therefore, non-white women may report using a greater total number of 
prescription medications compared to non-Hispanic white women, obscuring the frequency 
of oral contraceptive use among these groups in our analysis.
A strength of the current analysis is that the NHANES data are from a nationally 
representative, population-based sample of U.S. pregnant and non-pregnant women. 
NHANES oversampled pregnant women during the 1999–2006 survey cycles. The large 
number of non-pregnant women in our sample allowed us to estimate the prevalence of use 
of specific medications and to identify the most commonly reported medications among 
subgroups of this population.
This study was subject to certain limitations. Information on prescription medication use in 
the previous 30 days was based on self-report. However, prescription medication containers 
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were checked by trained interviewers which may have improved the accuracy of reported 
prescriptions, and the data captured reflect medications actually taken by the women, rather 
than relying on prescription dispensation records. In addition, the fact that participants were 
asked to recall only a short time period (30 days) may have assisted with accuracy. 
However, because participants were only queried about the previous 30 days, we were not 
able to assess prescription medication use throughout pregnancy. Because of the limitation 
to the previous 30 days, our results for the medications used by pregnant women are likely 
to underrepresent medications to treat acute symptoms or illnesses and are more likely to 
represent maintenance medications that are taken routinely. Pregnant women in their first 
trimester were also underrepresented in the NHANES sample because women had to be 
aware of their pregnancy status to be oversampled and included in the survey. Although the 
sample size was sufficient to estimate the percentage of pregnant women who reported 
taking a prescription medication in the past 30 days, the NHANES sample size was not 
sufficient to estimate the percentage of pregnant women taking specific medications or to 
allow for comparisons between these percentages in pregnant and non-pregnant women. 
Given that the total number of pregnant NHANES participants reporting each medication 
was relatively small (all N<25), the list of the most common medications should be 
interpreted with caution. Another limitation of the NHANES data is that it does not capture 
use of OTC medications, which is also important when considering exposure and safety 
during pregnancy.
In 2013 the Centers for Disease Control and Prevention convened an expert meeting to 
develop a systematic approach for evaluating and synthesizing existing data on medication 
use in pregnancy (55). This initiative, called Treating for Two, seeks to prevent adverse 
pregnancy outcomes related to maternal health conditions during pregnancy and to improve 
maternal health by providing women and their health care provider with the information 
they need for clinical decision making (see http://www.cdc.gov/pregnancy/meds/
treatingfortwo/). Gaps in knowledge identified by the proposed review process could help to 
set a research agenda for conditions and medications that are important to investigate in the 
future. Given the observed prevalence of prescription medication use in pregnant women 
and non-pregnant women of childbearing age, our data support the need for further studies 
investigating the safety profile of medications commonly used during pregnancy and among 
non-pregnant women of childbearing age. It will be important to repeat analyses of this 
nature with other U.S. data sources and to track trends and detect changing usage patterns as 
new medications come onto the market. Our findings document the importance of 
developing a broad evidence base with sufficient data to inform clinical decision-making 
and a need for accessible clinical guidelines to treat common conditions during pregnancy.
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Distribution of the number of prescription medications reported to have been taken in the 
previous 30 days among U.S. pregnant women and non-pregnant women of childbearing 
age, National Health and Nutrition Examination Survey (NHANES), 1999–2006
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Table 2
Most commonly reported prescription medications used in the previous 30 days among non-pregnant women 
of childbearing age (15–44 years) and pregnant women in the National Health and Nutrition Examination 
Survey (NHANES), 1999–2006
Ranka Medication Number of women reporting useb Percentage of women reporting 
usec
Typical indication
Non-pregnant women age 15–44 y
1 Ethinyl estradiol/norgestimated 155 3.7 (2.9, 4.7) Contraception
2 Levothyroxine 115 3.4 (2.7, 4.3) Thyroid disorder
3 Albuterol 149e 2.9 (2.3, 3.6) Asthma
4 Ibuprofen (prescription strength) 124e 2.7 (2.2, 3.4) Pain
5 Ethinyl estradiol/norethindroned 96 2.7 (2.1, 3.4) Contraception
6 Ethinyl estradiol/levonorgestreld 83 2.2 (1.6, 2.9) Contraception
7 Acetaminophen/hydrocodoned 94e 2.2 (1.7, 2.8) Pain
8 Fluoxetine 64 2.1 (1.6, 2.7) Depression/Anxiety
9 Sertraline 73 1.9 (1.5, 2.3) Depression/Anxiety
10 Paroxetine 60 NEf Depression/Anxiety
Pregnant women
1 Levothyroxine 24 NEf Thyroid disorder
2 Amoxicillin 21 Infection
3 Insulin 12e Diabetes
4 Nitrofurantoin 26 Infection
5 Albuterol 28 Asthma
6 Promethazine 13 Nausea/Allergy
7 Cetirizineg 8 Allergy
8 Montelukast 5 Asthma/Allergy
9 Sulfamethoxazole/trimethoprimd 4 Infection
10 Budesonide 2 Asthma/Allergy
a








8 women reported albuterol twice; 1 woman reported ibuprofen twice; 1 woman reported acetaminophen; hydrocodone twice; 7 women reported 
insulin twice
f
Not estimable; the degrees of freedom were less than 12 and the relative standard error was >30%
g
Became available without a prescription in 2006

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Matern Child Health J. Author manuscript; available in PMC 2016 May 01.
